Latest Nosology Stories

Silvia Mamede, M.D., Ph.D., of Erasmus University Rotterdam, the Netherlands and colleagues investigated whether recent experience with clinical problems provokes availability bias (overestimation of the likelihood of a diagnosis based on the ease with which it comes to mind) resulting in diagnostic errors and whether reflection (structured reanalysis of the case findings) counteracts this bias.The researchers conducted a study in 2009 with 18 first-year and 18 second-year internal medicine...

Researchers led by Philip Fernbach, a cognitive and linguistic sciences graduate student, have found that individuals are more likely to consider alternative causes when they make diagnoses than when they make decisions about the future. The findings suggest that framing problems as diagnostic-likelihood judgments can reduce bias. Details will be in the March 2010 edition of Psychological Science.PROVIDENCE, R.I. -- Brown University researchers have identified a way to improve thought...

SAN DIEGO, April 14 /PRNewswire/ -- XIFIN Inc., the leading provider of revenue cycle management for diagnostic laboratories, announced today that XIFIN's CEO and Executive Chairman, Lale White, will speak at the Executive War College Conference in New Orleans on April 28th 2009. In attendance will be senior executives, laboratory administrators and pathologists from many of the nation's largest laboratory organizations. (Logo: http://www.newscom.com/cgi-bin/prnh/20081013/LAM046LOGO) The...

SALT LAKE CITY, Oct. 7 /PRNewswire/ -- Great Basin Scientific, Inc., a privately held life sciences company developing novel, point-of-care molecular diagnostic solutions, today announced it had closed a $3.9 million financing round. New and returning investors participated in the funding for this round. The new round of financing will fund the company through the spring of 2009 as it completes the design of its rapid molecular diagnostic testing platform and brings a methicillin-resistant...

SUNNYVALE, Calif., Sept. 4 /PRNewswire/ -- Pathwork Diagnostics, a molecular diagnostics company focused on oncology, announced the closing today of a $20 million financing led by Abingworth. The announcement came on the heels of FDA's clearance for the Pathwork(R) Tissue of Origin Test for diagnosis of tumors of uncertain origin, including poorly differentiated, undifferentiated and metastatic tumors. "With this $20 million round of financing completed and the recent FDA clearance, the...